(–)-Clausenamide

5-HT2A Partial Agonism — The Psychoplastogen Signature#

The most recent and arguably most important mechanistic finding on (–)-clausenamide places it in the same family as TBG and AAZ-A-154: non-hallucinogenic psychoplastogens. The Olson lab at UC Davis demonstrated that (–)-cis-clausenamide is a low-efficacy partial agonist at the serotonin 5-HT2A receptor (BRET EC₅₀ ≈ 490 nM, Eₘₐₓ ≈ 28.4%) and drives cortical synaptogenesis in primary neuronal culture without producing psychedelic-like activation.

"(–)-cis-Clausenamide is a low-efficacy partial agonist at the serotonin 5-HT2A receptor and promotes cortical synaptogenesis without producing psychedelic effects in vitro." — Ou Y, et al. ACS Chemical Neuroscience, 2026

Practically, this is why the compound feels like nothing acutely. The 5-HT2A engagement is sub-threshold for perceptual effects but sufficient, over weeks, to drive structural plasticity. The cognitive payoff is a slow-build improvement in flexibility, learning rate, and mood resilience — not a stimulant punch.

Long-Term Potentiation in the Hippocampus#

The original Chinese pharmacology literature anchored (–)-clau as an LTP enhancer. In both anesthetized and freely moving rats, the (–) enantiomer potentiates basal synaptic transmission and amplifies high-frequency-stimulation-induced LTP in the dentate gyrus — a direct electrophysiological readout of the cellular substrate of memory consolidation. The (+) enantiomer is inactive at this endpoint, which is why enantiomeric purity is non-negotiable in sourcing.

"(–)-Clausenamide increased the magnitude of high frequency stimulation-induced long-term potentiation (LTP) in the dentate gyrus of anesthetized and freely moving rats." — Duan WZ, Zhang JT, et al. Journal of Neuroscience Research, 2005

This LTP enhancement is the mechanistic bridge between the molecular signalling described below and the memory-consolidation use case the nootropics community runs the compound for.

IP3R/Ca²⁺ → ERK1/2 → CREB Signalling#

Upstream of the LTP signature is a well-mapped intracellular cascade. In cortical neurons, (–)-clau mobilizes calcium from intracellular ER stores via the IP3 receptor and PLC-γ, with mitochondrial buffering shaping the transient. Downstream, the LTP-potentiating effect in the dentate gyrus is accompanied by phosphorylation of ERK1/2 and CREB — the canonical plasticity-and-gene-expression axis that BDNF–TrkB signalling also converges on.

This is the mechanistic rationale for stacking (–)-clau with BDNF-leaning inputs (7,8-DHF analogs, lion's mane, zone-2 cardio): two upstream signals converging on the same plasticity node should, in principle, produce a larger structural effect than either alone.

Aβ, Tau, and ER Stress — The Neuroprotective Arm#

Beyond plasticity, (–)-clau carries a documented neuroprotective profile that maps onto the longevity-oriented use case. Across a decade of pre-clinical work, the compound has been characterized as a multi-target anti-dementia candidate.

"(–)-Clausenamide improves cognition, inhibits β-amyloid toxicity, reduces tau hyperphosphorylation, and enhances synaptic plasticity in ten memory-impairment models." — Chu S, Liu S, Duan W, et al. Pharmacology & Therapeutics, 2016

The protective mechanism extends to acute ischemic-type insults as well. In cortical neurons exposed to oxygen-glucose deprivation and reoxygenation, (–)-clau suppresses the unfolded protein response arm that drives apoptotic commitment:

"(–)-Clausenamide treatment reduced apoptosis rates and inhibited the GRP78/eIF2α–ATF4–CHOP pathway in neurons exposed to OGD/R." — Zhang J, et al. Neurochemistry International, 2020

For physique-focused users running long blocks of high-androgen or high-stimulant stacks, this ER-stress and apoptosis-attenuation profile is the rationale for a low maintenance dose as a background neuroprotective input.

Why the Enantiomer Matters#

Clausenamide has four chiral centers and sixteen possible stereoisomers. The pharmacology splits cleanly along enantiomeric lines: the (–) form carries the plasticity, LTP, 5-HT2A, and neuroprotective signal, while the (+) form is inactive and more toxic.

"Pharmacological activity is essentially restricted to the (–) enantiomer, with (+)-clau inactive and more toxic. (–)-Clausenamide acts on multiple neurotransmitter systems and enhances long-term potentiation." — Chu SF, Zhang JT, Acta Pharmaceutica Sinica B, 2014

Practically: vendor COAs that don't specify the (–) enantiomer — and ideally the (–)-cis isomer — should be treated as racemic until proven otherwise. Racemic material delivers half the active compound plus the full toxic burden of the (+) form, which is the single most important sourcing rule for this compound.

Common (most users)#

The published toxicology on (–)-clausenamide is favorable, and community reports at sensible doses are largely uneventful. The effects that do show up are mild and dose-linked:

• Mild headache — most commonly reported in the first week, consistent with 5-HT2A engagement. Dropping back to the 5–10mg exploratory tier for 3–5 days, then titrating, usually resolves it. Hydration helps.
• Transient GI fullness or mild nausea — the lactam has modest aqueous solubility; pairing the dose with a fat-containing meal (the standard administration vehicle in community protocols) eliminates most of this.
• Subtle mood lift or "flatness" — both directions are reported. This tracks with low-Eₘₐₓ 5-HT2A partial agonism per Ou et al., 2026. Neither warrants intervention; the signal typically stabilizes by week 2.
• Mild sleep changes — vivid dreams or slightly fragmented sleep in the first week. Morning dosing (which is the default protocol anyway) is the mitigation.
• No "felt" acute effect at all — the most common "complaint" in r/Nootropics. (–)-clau is a slow-build synaptic plasticity compound driving ERK1/2–CREB and synaptogenesis, not an acute stimulant. Users expecting a racetam- or modafinil-style hit at day 3 are misreading the mechanism. The protocol calls for a 4–8 week assessment window.

Uncommon (dose-dependent or individual)#

These show up more often at the 50–100mg upper tier or in users with pre-existing serotonergic load:

• Persistent headache or mild vasoconstrictive sensations — back off to the 20–30mg range. Sustained headache at the upper tier is a clean signal that 5-HT2A occupancy is too high for that individual.
• Anxiety or jitteriness — uncommon but plausible given the serotonergic mechanism. More likely in users already on serotonergic agents (see contraindications). Dose reduction or discontinuation resolves it.
• GI upset beyond the first week — re-evaluate the suspension vehicle and meal pairing. Persistent GI symptoms past week 2 are not typical and warrant a pause.
• Cognitive blunting instead of enhancement — a small fraction of users report this. The mechanistic hypothesis is that low-Eₘₐₓ partial agonism behaves as functional antagonism in users with already-elevated endogenous 5-HT2A tone. Discontinue and the effect reverses.
• Bloodwork: no specific (–)-clau marker exists. On long runs (8+ weeks) a standard CMP and lipid panel every 3–6 months is the conservative play, given absent human PK data.

Rare but serious#

These have not been documented in the published (–)-clau literature, but the mechanism warrants flagging:

• Serotonin syndrome — when (–)-clau is combined with strong serotonergic agents (SSRIs, SNRIs, MAOIs, triptans, MDMA, tramadol, high-dose 5-HTP). Warning signs: agitation, tremor, hyperreflexia, diaphoresis, hyperthermia, clonus. Discontinue immediately and seek emergency care.
• Theoretical valvulopathy risk at chronic high exposure — the fen-phen / cabergoline-class concern attached to chronic 5-HT2B/2A engagement. (–)-clau is characterized as a low-Eₘₐₓ 5-HT2A partial agonist, not a 5-HT2B agonist, so the mechanistic risk is lower than the classic offenders — but no long-term human chronic-dosing data exist. Conservative users cap continuous runs at 8 weeks.
• Toxicity from racemic or (+)-contaminated material — the (+) enantiomer is inactive and more toxic per Chu & Zhang 2014. Symptoms would be non-specific (malaise, hepatic strain on bloodwork). This is a sourcing failure, not a compound failure.

Hard contraindications#

• SSRIs, SNRIs, MAOIs — serotonin syndrome risk. Not negotiable.
• Triptans, MDMA, tramadol, high-dose 5-HTP, St John's Wort — same mechanism; do not combine.
• History of serotonin syndrome — exclude.
• Known valvular heart disease or history of serotonergic-drug-induced valvulopathy — exclude.
• Racemic clausenamide or material without a chiral-HPLC COA confirming the (–) (ideally (–)-cis) enantiomer — do not source. The (+) form is both inactive and more toxic (Chu & Zhang 2014).
• Pregnancy or attempted conception — no reproductive toxicology data exist. Exclude.

Gender and PCT considerations#

No gender-specific dosing or safety signal is published. The pre-clinical literature is predominantly male rodent — female subject data are sparse, which is a gap rather than a red flag. (–)-clau is non-hormonal: no HPTA suppression, no aromatization, no androgenic signal, no hepatic-androgenic load. PCT is not required and not relevant. For looksmaxxing or AAS-running users layering (–)-clau onto an existing stack, the interaction surface is the serotonergic axis (above), not the endocrine axis — so the screening question is "what else is hitting 5-HT?", not "what's this doing to my HPTA?"